Patient Support Services Contact Us
Now Approved
The first and only pegfilgrastim-product autoinjector
Read the press release >

Immuno-oncology Begins Here

Developing immuno-oncology therapies for patients in need

The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.

We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.

About Coherus Immuno-oncology

Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines

Our approved products span multiple therapeutic areas including oncology, immunology and ophthalmology.

See our Products & Pipeline

Latest News

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
FDA Approves UDENYCA® Autoinjector
Coherus BioSciences to Present at Upcoming Investor Conferences in March